Business Context and Reporting Period
This Form 8-K is a current report filed by Halozyme Therapeutics, Inc. on May 3, 2021, covering the event date of May 1, 2021. The company is a Delaware corporation with its principal executive offices in San Diego, California, and its common stock trades on The Nasdaq Stock Market under the symbol HALO.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to reporting a corporate governance event.
Material Changes
The material change reported in this filing is the departure of a director:
- Event: Resignation of Kenneth J. Kelley from the Board of Directors.
- Date: May 1, 2021.
- Reason: Personal reasons.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It strictly addresses the resignation of a board member under Item 5.02.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Mr. Kelley's resignation.
- Confirm if a successor director has been appointed or if a vacancy remains.
- Review subsequent filings for any impact on corporate governance or strategic direction.